Waters Beats Q3 Estimates, Lifts Full-Year Revenue and EPS Outlook
WAT sits 62% above its 52-week low of $282.77 on elevated volume (2.4× avg).
Summary
Waters beat on both lines for Q3: sales of $1.77B topped the $1.75B consensus and adjusted EPS of $4.10 came in above the $4.00 estimate, with adjusted EPS up 21% year over year. Management raised full-year 2026 revenue guidance to $6.479B-$6.497B and lifted adjusted EPS to $14.60-$14.70, and guided Q4 to $1.801B-$1.819B in revenue and $4.58-$4.68 in adjusted EPS. The beat was broad: double-digit instrument and chemistry consumables growth in Analytical Sciences, high single-digit reagent growth in Biosciences (a 400bps acceleration), and LC-MS demand tied to replacement cycles plus GLP-1, PFAS and India generics. This follows the Q2 10-Q showing revenue more than doubled to $1.645B after the BDS acquisition but a $136M net loss on amortization and restructuring, so the raised outlook is the first clear sign the combined business is converting growth into earnings. The stock closed at $449.53 on November 2 and trades at 28x next-12-month earnings versus 24x three months ago, so the bar was already higher.
At the time of this announcement, WAT was trading at $457.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $44.2B. The 52-week trading range was $282.77 to $482.28. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.